IPM Take
The Second Universal Definition of Heart Failure is more than a terminology update. It is a challenge to the way health systems organise cardiovascular care. By emphasising early disease stages, underlying causes, trajectories, social drivers and geographic variation, the document effectively says that heart failure policy cannot remain hospital-centred. The next fight is implementation: who gets screened, who gets biomarkers, who gets imaging, who gets guideline-directed therapy, and who is left waiting until the first admission.
Executive Summary
An international expert consensus document, the Second Universal Definition of Heart Failure, was published on 29 June 2026 by the American Heart Association, American College of Cardiology, European Society of Cardiology and World Heart Federation, in collaboration with the Heart Failure Society of America, the Heart Failure Association of the ESC and the Japanese Heart Failure Society.
The document updates the 2021 First Universal Definition of Heart Failure and aims to standardise terminology for clinicians, researchers, health systems and policymakers. It introduces a universal classification of heart failure causes, shifts away from rigid left ventricular ejection fraction cutoffs, places greater emphasis on early stages of disease, and describes heart failure as dynamic, with potential for improvement, remission, recovery or progression.
The update also explicitly recognises that social determinants of health, geography, access to care and health policy environments shape heart failure risk and outcomes. That global framing matters. More than 64 million adults worldwide are estimated to live with heart failure, and the burden is rising as populations age and cardiometabolic risk factors increase.
The policy message is clear: heart failure cannot be managed only after symptoms appear. The new definition pushes health systems toward prevention, early detection, cause-specific diagnosis, better registries, more inclusive trials, and long-term surveillance of patients whose disease improves but does not necessarily disappear.
Why it matters
- Policymakers and public authorities: Heart failure prevention should be treated as a population health priority, not only as a hospital burden. Risk-factor control, early detection and access to diagnostics need stronger policy backing.
- Clinicians and providers: Heart failure should be understood by stage, cause and trajectory, not only by ejection fraction. Patients with improved function still need surveillance and tailored therapy.
- Payers and HTA bodies: Coverage decisions will need to reflect earlier diagnosis, biomarkers, imaging, cause-specific therapies, remote monitoring and prevention programmes before advanced disease develops.
- Data and AI leaders: Registries, AI-enabled ECG tools and predictive models will need recalibration around the new classification system, with validation across diverse populations and resource settings.
- Patients and advocates: The framework supports earlier recognition and more personalised care. But patients will only benefit if the definition changes real-world pathways, not just journal language.
Heart failure has a naming problem.
That may sound academic. It is not.
How a disease is defined determines who gets diagnosed, who gets coded, who gets enrolled in trials, who gets reimbursed, who gets treated early and who is ignored until the first hospitalisation.
That is why the Second Universal Definition of Heart Failure matters.
Published by major global cardiovascular societies in June 2026, the document updates the first universal definition from 2021 and tries to create a common language for clinicians, researchers, health systems and policymakers. The goal is not just semantic tidiness. It is to make heart failure prevention, diagnosis, classification and care more consistent across countries and health systems.
This is badly needed.
Heart failure affects more than 64 million adults worldwide. It is one of the clearest examples of a disease that is common, costly, disabling and often detected too late. Many patients first enter the system through breathlessness, fluid overload, emergency care or hospital admission, even though the biological and clinical risk began years earlier.
The new definition tries to pull the system upstream.
One of its most important shifts is the emphasis on early stages of disease. The document reaffirms the heart failure continuum from at-risk patients to pre-heart failure, symptomatic heart failure and advanced disease. That framing matters because it places prevention inside the heart failure pathway, not outside it.
In practical terms, this means hypertension, obesity, diabetes, chronic kidney disease, coronary disease, atrial fibrillation, valvular disease, cardiomyopathy and other risk states should not be treated as disconnected problems. They are part of the future heart failure pipeline.
A health system that waits for symptoms is already late.
The second major shift is away from rigid ejection fraction thinking. For years, left ventricular ejection fraction has dominated how heart failure is classified. It still matters. But the new definition recognises that strict cutoffs can obscure clinical reality, including variation by sex, age, ethnicity and imaging method. It groups heart failure into clinically actionable categories: reduced, preserved and improved ejection fraction.
That last category matters politically.
“Improved” is not the same as cured. Patients whose ejection fraction improves may still carry risk, need ongoing therapy and require monitoring. Too often, health systems treat improvement as permission to de-intensify follow-up. The new framework pushes back against that. Heart failure is dynamic. It can improve, remit, recover or progress.
Care pathways need to reflect that movement.
The third major shift is cause.
The document introduces a universal classification system for heart failure causes, moving beyond simplistic labels such as ischemic and non-ischemic. The listed causes include ischemic, hypertensive, valvular, arrhythmia-related, infiltrative, infective, inflammatory, toxic, heritable, pericardial, metabolic and nutritional, pregnancy-related, stress-induced, pulmonary or right-sided, congenital, high-output, other and idiopathic categories.
This is where heart failure moves closer to precision medicine.
A patient with amyloidosis, hypertensive heart disease, chemotherapy-related cardiomyopathy, pregnancy-related heart failure, inherited cardiomyopathy or valvular disease should not be collapsed into the same broad label. The underlying cause changes treatment, referral, family implications, prognosis and trial eligibility.
The new taxonomy should also improve registries and clinical trials. If everyone classifies causes differently, evidence becomes harder to compare. If trial populations are defined too narrowly around ejection fraction alone, therapies may be tested in ways that do not reflect real-world heterogeneity.
This is not just science. It is reimbursement architecture.
Payers and HTA bodies increasingly evaluate therapies by population, indication and outcomes. If heart failure categories become more cause-specific and trajectory-specific, coverage decisions will need to adapt. Biomarkers, imaging, genetic testing, amyloidosis diagnostics, cardio-oncology surveillance, postpartum follow-up and metabolic risk management may all become more central to value assessment.
The fourth shift is global equity.
The consensus document explicitly recognises that geography, access to care, social drivers of health and health policies shape heart failure risk and outcomes. That sentence should matter to policymakers.
Heart failure is not the same disease experience everywhere. In some settings, hypertension control is poor. In others, diabetes and obesity are rising. In some countries, rheumatic heart disease, Chagas disease, peripartum cardiomyopathy, infectious disease or limited access to imaging shape the burden. Even within high-income countries, diagnosis and outcomes vary by income, race, ethnicity, rurality, insurance, gender and access to specialist care.
A universal definition must not become a universal blindfold.
The point is not to pretend that every country has the same causes, resources or care pathways. The point is to build a common language that allows local realities to be seen more clearly.
That is especially important for global data.
If countries define and classify heart failure differently, the burden becomes harder to measure. If registries ignore etiology or social context, they will under-explain outcomes. If trials underrepresent regions where heart failure looks different, evidence will remain globally uneven.
The new definition creates the possibility of better surveillance. It does not guarantee it.
Implementation is now the real test.
For clinicians, the framework means asking earlier and deeper questions: is this patient at risk? Is this pre-heart failure? What is the likely cause? Is the ejection fraction reduced, preserved or improved? Is the patient improving, in remission, recovering or worsening? Are social barriers shaping outcomes? Is the current pathway treating the mechanism or just the syndrome?
For health systems, the questions are more uncomfortable.
Do primary care pathways identify pre-heart failure? Are natriuretic peptide tests accessible and reimbursed? Is echocardiography available quickly enough? Are hypertension, diabetes, kidney disease and obesity services connected to heart failure prevention? Are patients with improved ejection fraction followed or discharged into silence? Are registries capturing cause, trajectory and equity variables?
For policymakers, the issue is whether heart failure is still treated as a downstream cost.
Hospitalisations are visible. Prevention is quieter. That is why systems pay attention too late. The new definition makes it harder to justify that delay. It places early detection and individualised risk reduction at the centre.
The data and AI implications are also significant.
The AHA’s “Top Things to Know” summary notes that AI-enabled ECG is a promising tool for detecting left ventricular dysfunction and predicting incident heart failure, while stressing the need for validation in diverse populations and resource-limited settings. That caveat is essential. AI could help move heart failure detection upstream, especially where specialist imaging access is limited. But an unvalidated model can also widen disparities if it performs best in the populations and systems where it was trained.
AI should support the new definition. It should not create a new diagnostic divide.
There is also a danger of policy inertia. Consensus documents can be celebrated and then quietly ignored. The real-world effect will depend on whether the framework changes guidelines, quality metrics, registries, coding, reimbursement, trial design, clinical education and patient pathways.
The upcoming AHA/ACC Heart Failure Guideline, expected in late 2027, will be an important test. But other systems should not wait. The logic of the new definition is already clear: heart failure care must move earlier, become more cause-specific, and reflect global variation.
A better definition will not lower a patient’s blood pressure. It will not prescribe an SGLT2 inhibitor. It will not order an echocardiogram. It will not screen a family for inherited cardiomyopathy. It will not fund rural heart failure clinics.
But definitions shape whether those actions become expected. The Second Universal Definition of Heart Failure gives the field a better map. Now health systems have to stop pretending the map is the journey.
